Shattuck Labs. has been granted a patent for compositions and methods involving chimeric proteins and combination therapies aimed at treating diseases like cancer and inflammatory conditions. The patent specifically details a method for targeting tumors expressing CSF1, CEACAM1, and galectin-9 using specific chimeric proteins. GlobalData’s report on Shattuck Labs gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Shattuck Labs, Peptide pharmacophores was a key innovation area identified from patents. Shattuck Labs's grant share as of July 2024 was 10%. Grant share is based on the ratio of number of grants to total number of patents.
Chimeric proteins for treating tumors and inflammatory diseases
The granted patent US12071465B2 outlines a novel method for treating tumors that express specific biomarkers, namely CSF1, CEACAM1, and galectin-9. The treatment involves the administration of two distinct chimeric proteins. The first chimeric protein consists of an extracellular domain of TIM3 linked to an extracellular domain of OX40L via a linker that includes at least one cysteine residue capable of forming a disulfide bond. The second chimeric protein comprises an extracellular domain of CSF1R linked to an extracellular domain of CD40L, also utilizing a similar linker structure. The claims specify that the order of administration of these chimeric proteins can vary, allowing for flexibility in treatment protocols.
Further details in the claims emphasize the structural requirements of the linkers and the extracellular domains, stipulating that they must exhibit at least 95% identity to specific amino acid sequences provided in the patent. The linkers may include flexible amino acid sequences or hinge regions from IgG4, with additional joining linkers potentially enhancing the structural integrity of the chimeric proteins. The patent also extends its application to the treatment of colon cancer, reiterating the same chimeric protein structures and administration methods. Overall, this patent presents a targeted therapeutic approach that leverages engineered proteins to potentially improve treatment outcomes for specific tumor types.
To know more about GlobalData’s detailed insights on Shattuck Labs, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
